Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives.

@article{Oeckl2015CerebrospinalFP,
  title={Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives.},
  author={Patrick Oeckl and Petra Steinacker and Emily Feneberg and Markus Otto},
  journal={Biochimica et biophysica acta},
  year={2015},
  volume={1854 7},
  pages={757-68}
}
Frontotemporal lobar degeneration (FTLD) comprises a spectrum of rare neurodegenerative diseases with an estimated prevalence of 15-22 cases per 100,000 persons including the behavioral variant of frontotemporal dementia (bvFTD), progressive non-fluent aphasia (PNFA), semantic dementia (SD), FTD with motor neuron disease (FTD-MND), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). The pathogenesis of the diseases is still unclear and clinical diagnosis of FTLD is hampered by… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Novel CSF biomarkers to discriminate FTLD and its pathological subtypes

Annals of clinical and translational neurology • 2018
View 3 Excerpts

Similar Papers

Loading similar papers…